Core Viewpoint - Dingtang Health (09886) has seen a stock price increase of over 5%, currently up 6.82% to HKD 0.94, with a trading volume of HKD 5.24 million, following a partnership announcement with Eli Lilly [1] Group 1: Company Developments - Dingtang Health has officially launched the injection of Tirzepatide (Mufengda) in pharmacies in Guangzhou and Shenzhen, expanding its collaboration with Eli Lilly beyond Beijing [1] - The partnership aims to provide a one-stop health solution for overweight/obese and diabetic populations, enhancing medication accessibility and health management levels [1] Group 2: Market Context - According to Tianfeng Securities, over 2.6 billion people globally were affected by overweight/obesity in 2020, indicating a growing weight loss market [1] - Eli Lilly is recognized as a leading company in the weight loss sector, which aligns with the strategic goals of Dingtang Health [1]
港股异动 | 叮当健康(09886)涨超5% 公司加码减重市场布局 推进与原研药企合作